|
Gene: MAP1B |
Gene summary for MAP1B |
Gene summary. |
Gene information | Species | Human | Gene symbol | MAP1B | Gene ID | 4131 |
Gene name | microtubule associated protein 1B | |
Gene Alias | FUTSCH | |
Cytomap | 5q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | A2BDK6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4131 | MAP1B | AEH-subject2 | Human | Endometrium | AEH | 1.19e-04 | 1.89e-01 | -0.2525 |
4131 | MAP1B | EEC-subject2 | Human | Endometrium | EEC | 2.56e-05 | 3.23e-01 | -0.2607 |
4131 | MAP1B | GSM5276934 | Human | Endometrium | EEC | 2.53e-08 | 3.93e-01 | -0.0913 |
4131 | MAP1B | GSM5276937 | Human | Endometrium | EEC | 2.57e-20 | 6.81e-01 | -0.0897 |
4131 | MAP1B | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 1.29e-09 | -2.22e-01 | -0.1869 |
4131 | MAP1B | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 6.02e-07 | -2.21e-01 | -0.1875 |
4131 | MAP1B | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 8.54e-10 | -2.55e-01 | -0.1883 |
4131 | MAP1B | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 3.00e-11 | -1.67e-01 | -0.1934 |
4131 | MAP1B | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.60e-10 | -2.40e-01 | -0.1917 |
4131 | MAP1B | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 3.02e-15 | -2.70e-01 | -0.1916 |
4131 | MAP1B | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 5.19e-03 | -2.10e-01 | -0.1269 |
4131 | MAP1B | LZE4T | Human | Esophagus | ESCC | 4.01e-41 | 1.66e+00 | 0.0811 |
4131 | MAP1B | LZE7T | Human | Esophagus | ESCC | 1.36e-23 | 1.80e+00 | 0.0667 |
4131 | MAP1B | LZE21T | Human | Esophagus | ESCC | 3.61e-11 | 7.30e-01 | 0.0655 |
4131 | MAP1B | P2T-E | Human | Esophagus | ESCC | 5.72e-19 | 6.71e-01 | 0.1177 |
4131 | MAP1B | P4T-E | Human | Esophagus | ESCC | 2.15e-19 | 9.00e-01 | 0.1323 |
4131 | MAP1B | P5T-E | Human | Esophagus | ESCC | 1.75e-13 | 5.28e-01 | 0.1327 |
4131 | MAP1B | P8T-E | Human | Esophagus | ESCC | 5.23e-03 | 1.84e-01 | 0.0889 |
4131 | MAP1B | P9T-E | Human | Esophagus | ESCC | 7.57e-36 | 1.10e+00 | 0.1131 |
4131 | MAP1B | P10T-E | Human | Esophagus | ESCC | 4.01e-12 | 2.73e-01 | 0.116 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00486759 | Oral cavity | OSCC | axon extension | 61/7305 | 120/18723 | 5.52e-03 | 2.14e-02 | 61 |
GO:00436244 | Oral cavity | OSCC | cellular protein complex disassembly | 68/7305 | 136/18723 | 5.84e-03 | 2.24e-02 | 68 |
GO:190290417 | Oral cavity | OSCC | negative regulation of supramolecular fiber organization | 81/7305 | 167/18723 | 7.70e-03 | 2.82e-02 | 81 |
GO:001635810 | Oral cavity | OSCC | dendrite development | 113/7305 | 243/18723 | 1.00e-02 | 3.49e-02 | 113 |
GO:006156410 | Oral cavity | OSCC | axon development | 207/7305 | 467/18723 | 1.01e-02 | 3.51e-02 | 207 |
GO:00516462 | Oral cavity | OSCC | mitochondrion localization | 28/7305 | 50/18723 | 1.10e-02 | 3.72e-02 | 28 |
GO:003238616 | Oral cavity | LP | regulation of intracellular transport | 145/4623 | 337/18723 | 8.58e-14 | 8.27e-12 | 145 |
GO:0022411110 | Oral cavity | LP | cellular component disassembly | 173/4623 | 443/18723 | 9.97e-12 | 7.44e-10 | 173 |
GO:0043254110 | Oral cavity | LP | regulation of protein-containing complex assembly | 163/4623 | 428/18723 | 3.72e-10 | 1.92e-08 | 163 |
GO:0031334110 | Oral cavity | LP | positive regulation of protein-containing complex assembly | 99/4623 | 237/18723 | 4.83e-09 | 2.00e-07 | 99 |
GO:005165615 | Oral cavity | LP | establishment of organelle localization | 147/4623 | 390/18723 | 6.01e-09 | 2.46e-07 | 147 |
GO:0051258110 | Oral cavity | LP | protein polymerization | 113/4623 | 297/18723 | 1.90e-07 | 5.92e-06 | 113 |
GO:0031667110 | Oral cavity | LP | response to nutrient levels | 165/4623 | 474/18723 | 3.87e-07 | 1.12e-05 | 165 |
GO:001063919 | Oral cavity | LP | negative regulation of organelle organization | 127/4623 | 348/18723 | 5.07e-07 | 1.40e-05 | 127 |
GO:0032273110 | Oral cavity | LP | positive regulation of protein polymerization | 60/4623 | 138/18723 | 1.00e-06 | 2.50e-05 | 60 |
GO:0032271110 | Oral cavity | LP | regulation of protein polymerization | 89/4623 | 233/18723 | 3.00e-06 | 6.47e-05 | 89 |
GO:1902905110 | Oral cavity | LP | positive regulation of supramolecular fiber organization | 81/4623 | 209/18723 | 4.30e-06 | 8.80e-05 | 81 |
GO:003109916 | Oral cavity | LP | regeneration | 76/4623 | 198/18723 | 1.25e-05 | 2.24e-04 | 76 |
GO:1902903110 | Oral cavity | LP | regulation of supramolecular fiber organization | 131/4623 | 383/18723 | 1.58e-05 | 2.78e-04 | 131 |
GO:000961215 | Oral cavity | LP | response to mechanical stimulus | 81/4623 | 216/18723 | 1.80e-05 | 3.09e-04 | 81 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa032509 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0325014 | Esophagus | ESCC | Viral life cycle - HIV-1 | 54/4205 | 63/8465 | 2.01e-09 | 2.17e-08 | 1.11e-08 | 54 |
hsa0325022 | Oral cavity | LP | Viral life cycle - HIV-1 | 32/2418 | 63/8465 | 1.55e-04 | 9.08e-04 | 5.86e-04 | 32 |
hsa0325031 | Oral cavity | LP | Viral life cycle - HIV-1 | 32/2418 | 63/8465 | 1.55e-04 | 9.08e-04 | 5.86e-04 | 32 |
hsa032506 | Oral cavity | NEOLP | Viral life cycle - HIV-1 | 16/1112 | 63/8465 | 6.21e-03 | 2.33e-02 | 1.46e-02 | 16 |
hsa032507 | Oral cavity | NEOLP | Viral life cycle - HIV-1 | 16/1112 | 63/8465 | 6.21e-03 | 2.33e-02 | 1.46e-02 | 16 |
hsa032504 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
hsa0325012 | Prostate | BPH | Viral life cycle - HIV-1 | 24/1718 | 63/8465 | 8.32e-04 | 3.98e-03 | 2.46e-03 | 24 |
hsa0325021 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
hsa032503 | Prostate | Tumor | Viral life cycle - HIV-1 | 25/1791 | 63/8465 | 6.13e-04 | 3.07e-03 | 1.91e-03 | 25 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP1B | SNV | Missense_Mutation | c.254N>A | p.Arg85Gln | p.R85Q | P46821 | protein_coding | deleterious(0.04) | probably_damaging(0.994) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MAP1B | SNV | Missense_Mutation | c.2220N>T | p.Lys740Asn | p.K740N | P46821 | protein_coding | deleterious(0) | possibly_damaging(0.879) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MAP1B | SNV | Missense_Mutation | novel | c.6534N>G | p.Ile2178Met | p.I2178M | P46821 | protein_coding | tolerated(0.25) | probably_damaging(0.984) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
MAP1B | SNV | Missense_Mutation | rs6876207 | c.3662N>G | p.Ser1221Cys | p.S1221C | P46821 | protein_coding | deleterious(0) | probably_damaging(0.921) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MAP1B | insertion | Frame_Shift_Ins | novel | c.6042_6043insGGGCTTC | p.Thr2015GlyfsTer7 | p.T2015Gfs*7 | P46821 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
MAP1B | insertion | Frame_Shift_Ins | novel | c.1478_1479insGTATCTGCAGAGAATATGCTGGGTGACCCACTCATGTTTCAAT | p.Ser493ArgfsTer62 | p.S493Rfs*62 | P46821 | protein_coding | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
MAP1B | insertion | Frame_Shift_Ins | novel | c.2748_2749insTGCATGATCCAAAATACTTTATTTCTATGGCTCATTGCCAA | p.Lys917CysfsTer18 | p.K917Cfs*18 | P46821 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
MAP1B | insertion | Frame_Shift_Ins | novel | c.4966_4967insGCAGAGGCAG | p.Gln1656ArgfsTer29 | p.Q1656Rfs*29 | P46821 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
MAP1B | insertion | Frame_Shift_Ins | novel | c.4968_4969insGTAGCCCCGGTGTCTCCTGAGGTGACCCAAGAAG | p.Ser1657ValfsTer36 | p.S1657Vfs*36 | P46821 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
MAP1B | insertion | Frame_Shift_Ins | novel | c.1503_1504insGAGATGAGGT | p.Leu502GlufsTer42 | p.L502Efs*42 | P46821 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |